Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a senior executive told Reuters on Thursday.

Novo Nordisk adding in-house fill-finish capacity for Wegovy's European pen, Ozempic

Comcast

Li Auto Inc.

Eli Lilly

NVIDIA

Symbotic Inc

Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.

7 A-Rated Tech Stocks to Buy for November

Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from its century-long focus on insulin.

Novo Nordisk: obesity drugs priority over century-old focus on insulin

Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.

Ozempic Sales Up 58% As Drugmaker Novo Nordisk Nets Record Profits

Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.

Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies

Shares in Europe's largest drugs company rose 1.6% in early trade boosted by the performance of its breakthrough weight loss drug Wegovy. Novo Nordisk (NYSE:NVO) said sales of obesity medication increased by 167% to DKr30.4 billion, while revenue from diabetes medications rose by 45%.

Novo Nordisk shares higher on bumper Wegovy boost

Novo Nordisk on Thursday reported record sales and operating profits for the third quarter but flagged continued restrictions on supplies of its hugely popular Wegovy weight-loss drug.

Novo Nordisk flags continued restrictions on Wegovy supplies

Bagsværd 2 November 2023 - Financial report for the period 1 January 2023 to 30 September 2023

Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023

The earnings report comes amid what has been a surprisingly grim two weeks for the pharmaceutical stocks.

Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drugs.

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice

FUJIFILM Holdings Corp

Novo Nordisk has hired FUJIFILM Diosynth Biotechnologies to fill Wegovy injection pens, a source familiar with the matter told Reuters, as the Danish drugmaker scrambles to boost output of its hugely popular weight-loss drug.

Exclusive: Novo hires FUJIFILM unit to help make Wegovy weight-loss drug - source

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Novo Nordisk (NVO) Ahead of Earnings?

Novo Nordisk is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy.

How Novo Nordisk makes its weight-loss drug Wegovy

Viatris

Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be evaluated in depth.

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?

MARSEILLE, France--(BUSINESS WIRE)--Vect-Horus announced it has entered into a global license agreement with Novo Nordisk A/S.

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Novo Nordisk just acquired a promising pharmaceutical asset for kidney disease. The candidate could also address hypertension, so the potential market could be huge.

Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?

Rather than holding out for big gains in a tough market, our selling into strength made this stock a winner.

NVO Stock Ended Up Being Healthy For Swing Trading Portfolios

West Pharmaceutical Services

Soaring demand for obesity drugs was in the spotlight at the world's largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens.

Weight-loss drugs in spotlight as pharma services firms rush to snap up business

DaVita

DexCom

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?

Insulet

Tandem Diabetes Care

Diabetes-device makers' stocks are breaking out of ‘GLP-1 jail' ahead of schedule, analysts say, after months of stock-market punishment based on fears that the popular obesity drugs would clobber the market for their products.

Diabetes stocks jump as obesity-drug recovery comes ahead of schedule, analysts say

Costco

Taiwan Semiconductor Manufacturing

Over the past 100 years, the stock market has proved to be the best way to build wealth. Even through recessions, depressions, and world wars, growth stocks generate better returns than any other asset class.

3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K

When Novo Nordisk publishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease.

Novo investors seek clarity on Wegovy weight-loss drug shortages

Novo Nordisk has reported strong revenue and profit growth over the past five years. The company recently upgraded its guidance for 2023.

Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.

Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 billion, compared to $0.90 per share on revenue of $6.47 billion a year earlier.  Ozempic has seen a huge surge in sales, leading the company to increase its annual sales growth guidance earlier this month.

Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week

NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030. This has led to the stock's inflated P/E premium near to the pharmaceutical leaders, due to the market's optimism about its profitable growth trend and potential applications for new indications. Then again, NVO's supply constraints and potential competition may limit its upside potential moving forward, made uncertain by the US government's crack-down on prescription costs.

News for Novo Nordisk Stock (NVO)